Pharmaceuticals & Drugs · Founded 1992 · www.keralaayurveda.biz · BSE 530163 · · ISIN INE817B01025
No Notes Added Yet
Business
Kerala Ayurveda Ltd. is an Indian company engaged in the manufacturing, marketing, and distribution of Ayurvedic products, along with providing Ayurvedic healthcare services. Its core business model is integrated, encompassing the production of classical and proprietary Ayurvedic medicines, dietary supplements, and personal care products, as well as operating Ayurvedic hospitals, wellness resorts, and clinics. The company also offers Ayurvedic education and training programs. Kerala Ayurveda makes money through the sale of its Ayurvedic formulations, revenue generated from its healthcare services (consultations, therapies, treatments), and fees from its educational initiatives, catering to both domestic and international markets.
Revenue Mix
While specific revenue contributions are not publicly detailed, Kerala Ayurveda Ltd.'s operations can be broadly categorized into:
Products: Manufacturing and sale of Ayurvedic medicines, herbal supplements, classical formulations, proprietary products, and personal care items. This segment likely forms a significant portion of revenue.
Services: Operating Ayurvedic hospitals, wellness centers, and clinics offering consultations, therapeutic treatments, and rejuvenation programs.
Education & Training: Providing courses and certifications in Ayurveda to students and practitioners.
Exports: Sales of its products and services to international markets.
Industry
Kerala Ayurveda operates within the Indian Pharmaceuticals & Drugs sector, specifically within the rapidly growing Ayurveda industry. The broader Indian AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy) market is characterized by increasing consumer preference for natural remedies and wellness solutions, supported by government initiatives. The industry is fragmented, with a mix of large established players, regional companies, and numerous unorganized units. Kerala Ayurveda positions itself as an established, heritage brand with a focus on authentic classical Ayurvedic formulations and an integrated approach that combines product manufacturing with healthcare services and education. It leverages its "Kerala Ayurveda" brand, which carries a perception of authenticity and tradition, distinguishing it from general wellness brands or pure pharmaceutical players.
MOAT
Brand & Heritage: The "Kerala Ayurveda" brand itself evokes trust, authenticity, and traditional knowledge, which is a significant asset in the Ayurveda sector where consumer confidence in efficacy and purity is paramount. Its long-standing presence provides a legacy advantage.
Integrated Model: The combination of product manufacturing, healthcare services (clinics, hospitals, resorts), and education creates a synergistic ecosystem. This allows for direct feedback, research opportunities, and a comprehensive customer journey, potentially increasing customer loyalty and product adoption.
Deep Knowledge Base: Access to traditional Ayurvedic texts, experienced practitioners, and formulation expertise built over decades contributes to a strong R&D foundation for developing classical and proprietary products.
Growth Drivers
Increasing Awareness & Acceptance: Growing global and domestic demand for natural, holistic, and preventive healthcare solutions, coupled with rising interest in traditional medicine systems like Ayurveda.
Government Support: Initiatives by the Indian government (e.g., Ministry of AYUSH) promoting traditional medicine, standardization, and research.
Expansion of Distribution & Reach: Growing sales through modern trade, e-commerce platforms, and expanding clinic/resort footprint, both domestically and internationally.
Product Portfolio Expansion: Introduction of new classical and proprietary products in response to evolving consumer health needs.
Wellness Tourism: Leveraging its wellness resorts and services to tap into the growing health and medical tourism market.
Risks
Regulatory Scrutiny: Products, especially herbal medicines, face evolving regulatory challenges related to quality, efficacy claims, and ingredient sourcing in various markets.
Competition: Intense competition from other established Ayurvedic companies (e.g., Dabur, Patanjali, Himalaya), regional players, and conventional pharmaceutical companies entering the herbal segment.
Raw Material Volatility: Dependence on seasonal and often wild-crafted medicinal plants makes the company susceptible to price fluctuations, availability issues, and supply chain disruptions.
Quality Control & Standardization: Maintaining consistent quality and efficacy across a wide range of products and services is critical for brand reputation and consumer trust.
Perception & Efficacy: Challenges in establishing and proving scientific efficacy in line with modern medical standards, potentially leading to skepticism among some consumer segments.
Management & Ownership
Kerala Ayurveda Ltd. is typically a promoter-led company, characteristic of many heritage Indian businesses. The promoters usually bring a deep understanding of the core Ayurvedic principles and a long-term vision rooted in tradition. As a publicly listed entity, it would have a professional management team overseeing day-to-day operations and strategic growth, balancing traditional values with modern business practices. Ownership structure would include the promoter group holding a significant stake, alongside institutional and public shareholders.
Outlook
Kerala Ayurveda Ltd. operates in an industry experiencing significant tailwinds due to increasing health consciousness, a preference for natural solutions, and growing government support for traditional medicine. Its established brand, integrated business model, and legacy in authentic Ayurveda provide a strong foundation. The bull case hinges on the company's ability to effectively leverage its brand for geographical expansion, innovate its product portfolio, and scale its service offerings while maintaining strict quality control and regulatory compliance. The bear case involves challenges from intense competition, potential issues with raw material sourcing and pricing, and the ability to adapt to changing consumer demands and evolving regulatory landscapes, particularly concerning scientific validation and standardization of Ayurvedic products globally. Its future performance will depend on its capacity to blend traditional wisdom with modern business acumen and execution.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 25 | 32 | 27 | 30 | 31 | 31 | 29 | 35 | 33 | 35 |
| Other Income | 0 | -0 | 0 | 1 | 0 | 1 | 9 | 2 | 1 | 2 |
| Total Income | 25 | 32 | 28 | 31 | 31 | 32 | 38 | 37 | 34 | 37 |
| Total Expenditure | 24 | 27 | 27 | 25 | 32 | 41 | 33 | 40 | 34 | 42 |
| Operating Profit | 1 | 5 | 1 | 6 | -1 | -9 | 5 | -3 | -0 | -5 |
| Interest | 1 | 3 | 0 | 1 | 0 | 2 | 1 | 3 | 3 | 1 |
| Depreciation | 0 | 1 | 0 | 2 | 1 | 2 | 2 | 1 | 1 | 2 |
| Exceptional Income / Expenses | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 3 | -2 | -14 | 3 | -7 | -4 | -8 |
| Provision for Tax | 1 | -0 | -0 | -0 | 1 | 2 | 1 | -0 | 0 | -1 |
| Profit After Tax | -1 | 1 | 0 | 4 | -3 | -15 | 2 | -6 | -5 | -7 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 |
| Profit After Adjustments | -1 | 0 | 0 | 3 | -3 | -16 | 2 | -6 | -4 | -8 |
| Adjusted Earnings Per Share | -0.9 | 0.2 | 0.3 | 2.8 | -2.4 | -12.9 | 1.7 | -5.3 | -3.7 | -6.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 39 | 46 | 50 | 56 | 62 | 77 | 62 | 80 | 93 | 108 | 120 | 132 |
| Other Income | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 14 |
| Total Income | 39 | 46 | 51 | 56 | 63 | 77 | 62 | 81 | 94 | 108 | 123 | 146 |
| Total Expenditure | 33 | 39 | 43 | 48 | 57 | 69 | 61 | 71 | 91 | 101 | 125 | 149 |
| Operating Profit | 6 | 8 | 7 | 8 | 5 | 7 | 1 | 10 | 3 | 7 | -3 | -3 |
| Interest | 2 | 2 | 1 | 2 | 3 | 2 | 6 | 7 | 5 | 5 | 4 | 8 |
| Depreciation | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 0 | 0 |
| Profit Before Tax | 3 | 4 | 4 | 4 | 3 | 5 | -7 | 3 | -1 | 1 | -12 | -16 |
| Provision for Tax | 1 | 1 | 1 | 1 | 1 | 0 | -2 | 0 | -0 | 2 | 2 | 0 |
| Profit After Tax | 3 | 3 | 3 | 3 | 3 | 4 | -5 | 2 | -0 | -1 | -14 | -16 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -1 | -1 | 0 |
| Profit After Adjustments | 2 | 3 | 3 | 3 | 2 | 4 | -5 | 2 | -1 | -2 | -15 | -16 |
| Adjusted Earnings Per Share | 2.2 | 2.6 | 2.9 | 2.7 | 2.3 | 3.7 | -4.6 | 2.2 | -0.5 | -1.3 | -12.2 | -13.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 11% | 14% | 9% | 12% |
| Operating Profit CAGR | -143% | NAN% | NAN% | NAN% |
| PAT CAGR | 0% | NAN% | NAN% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -53% | 17% | 28% | 13% |
| ROE Average | -86% | -36% | -30% | 81% |
| ROCE Average | -9% | 1% | 3% | 6% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | -9 | -6 | 7 | 8 | 4 | 8 | 3 | 6 | 6 | 32 | 9 |
| Minority's Interest | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| Borrowings | 54 | 52 | 20 | 43 | 50 | 52 | 59 | 37 | 50 | 59 | 18 |
| Other Non-Current Liabilities | -1 | 1 | 4 | 5 | 10 | 10 | 8 | 5 | 4 | 6 | 5 |
| Total Current Liabilities | 25 | 24 | 48 | 45 | 28 | 31 | 42 | 60 | 53 | 40 | 88 |
| Total Liabilities | 71 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 141 | 124 |
| Fixed Assets | 33 | 34 | 34 | 32 | 33 | 33 | 33 | 44 | 46 | 46 | 47 |
| Other Non-Current Assets | 24 | 25 | 25 | 28 | 31 | 34 | 34 | 26 | 31 | 31 | 36 |
| Total Current Assets | 14 | 14 | 22 | 42 | 28 | 33 | 44 | 37 | 35 | 60 | 41 |
| Total Assets | 71 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 141 | 124 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 2 | 2 | 3 | 7 | 5 | 6 | 19 | 3 | 4 | 23 |
| Cash Flow from Operating Activities | 0 | 6 | 4 | -10 | 12 | 5 | 7 | -1 | 10 | 2 | 5 |
| Cash Flow from Investing Activities | -0 | -3 | -3 | -3 | -3 | -4 | -1 | -2 | -7 | -1 | -15 |
| Cash Flow from Financing Activities | 2 | -3 | 0 | 17 | -12 | 1 | 6 | -13 | -1 | 18 | -9 |
| Net Cash Inflow / Outflow | 2 | -0 | 1 | 4 | -2 | 2 | 12 | -16 | 2 | 18 | -19 |
| Closing Cash & Cash Equivalent | 2 | 2 | 3 | 7 | 5 | 6 | 19 | 3 | 4 | 23 | 3 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.23 | 2.56 | 2.9 | 2.66 | 2.32 | 3.69 | -4.59 | 2.24 | -0.51 | -1.3 | -12.22 |
| CEPS(Rs) | 3.47 | 4.48 | 4.79 | 4.46 | 3.32 | 4.92 | -3.38 | 3.41 | 0.64 | 0.4 | -7.47 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -8.44 | -5.88 | 6.6 | 7.49 | 3.53 | 4.65 | 0.37 | 2.93 | 2.57 | 24.13 | 2.71 |
| Core EBITDA Margin(%) | 14.26 | 14.67 | 13.42 | 13.71 | 7.82 | 9.58 | 1.35 | 11.86 | 2.81 | 6.26 | -3.98 |
| EBIT Margin(%) | 11.9 | 11.62 | 10.4 | 11.05 | 9.12 | 8.12 | -0.52 | 11.79 | 4.96 | 5.5 | -6.19 |
| Pre Tax Margin(%) | 7.66 | 8.45 | 7.75 | 7.08 | 4.98 | 5.91 | -10.86 | 3.49 | -0.6 | 1.18 | -9.74 |
| PAT Margin (%) | 6.07 | 5.63 | 6.08 | 4.89 | 4.06 | 5.28 | -7.8 | 2.98 | -0.46 | -0.8 | -11.11 |
| Cash Profit Margin (%) | 8.83 | 9.72 | 9.37 | 8 | 5.64 | 6.77 | -5.74 | 4.47 | 0.73 | 0.45 | -7.15 |
| ROA(%) | 3.72 | 3.81 | 4.27 | 3.14 | 2.59 | 4.15 | -4.47 | 2.14 | -0.38 | -0.67 | -10.55 |
| ROE(%) | 0 | 0 | 862.54 | 38.72 | 43.39 | 93.9 | -183.03 | 137.66 | -14.76 | -5.44 | -86.43 |
| ROCE(%) | 8.35 | 9.15 | 8.91 | 8.88 | 7.64 | 9.27 | -0.45 | 12.62 | 6.18 | 6.75 | -8.94 |
| Receivable days | 31.35 | 29.69 | 30.44 | 31.76 | 36.2 | 41.85 | 61.85 | 53.75 | 51.38 | 48.66 | 51 |
| Inventory Days | 49.56 | 45.53 | 52.95 | 62.41 | 64.65 | 58.03 | 70.07 | 52.19 | 47.8 | 47.37 | 41.35 |
| Payable days | 187.68 | 141.98 | 123.71 | 142.11 | 134.74 | 164.33 | 186.13 | 183.24 | 169.01 | 155.66 | 128.93 |
| PER(x) | 17.32 | 21.28 | 32.09 | 31.63 | 28.84 | 9.91 | 0 | 34.93 | 0 | 0 | 0 |
| Price/Book(x) | -4.58 | -9.26 | 14.09 | 11.24 | 18.92 | 7.87 | 140.57 | 26.68 | 32.49 | 10.83 | 129.43 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 2.78 | 2.7 | 3.01 | 2.82 | 2.05 | 1.26 | 1.81 | 1.86 | 1.69 | 3.35 | 4.03 |
| EV/Core EBITDA(x) | 17.85 | 16.22 | 20.53 | 18.87 | 23.76 | 13.07 | 117.92 | 15.14 | 54.32 | 49.67 | -173 |
| Net Sales Growth(%) | 11.98 | 17.73 | 9.72 | 10.67 | 11.46 | 23.46 | -19.15 | 29.45 | 16.25 | 15.46 | 11.57 |
| EBIT Growth(%) | 64.68 | 14.54 | -0.74 | 15.99 | -12.78 | 9.92 | -105.22 | 3011.19 | -51.06 | 27.92 | -231.23 |
| PAT Growth(%) | 173.76 | 8.82 | 19.8 | -12.18 | -12.37 | 60.63 | -219.5 | 149.42 | -117.89 | -101.52 | -1517.68 |
| EPS Growth(%) | 216.58 | 14.68 | 13.24 | -8.19 | -12.95 | 59.43 | -224.28 | 148.76 | -122.61 | -156.74 | -840.72 |
| Debt/Equity(x) | -7.86 | -11.05 | 8.1 | 9.51 | 16.57 | 13.08 | 198.89 | 22.6 | 27.42 | 2.4 | 20.21 |
| Current Ratio(x) | 0.54 | 0.56 | 0.45 | 0.93 | 1.03 | 1.08 | 1.04 | 0.61 | 0.67 | 1.49 | 0.46 |
| Quick Ratio(x) | 0.3 | 0.32 | 0.25 | 0.7 | 0.61 | 0.66 | 0.78 | 0.42 | 0.43 | 1.1 | 0.32 |
| Interest Cover(x) | 2.81 | 3.67 | 3.93 | 2.78 | 2.2 | 3.67 | -0.05 | 1.42 | 0.89 | 1.27 | -1.75 |
| Total Debt/Mcap(x) | 1.72 | 1.19 | 0.57 | 0.85 | 0.88 | 1.66 | 1.41 | 0.85 | 0.84 | 0.22 | 0.16 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.44 | 58.58 | 58.58 | 58.58 | 58.58 | 58.58 | 37.83 | 33.14 | 33.14 | 35.61 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.22 | 0.17 |
| DII | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Public | 36.52 | 41.38 | 41.38 | 41.38 | 41.38 | 41.38 | 62.13 | 66.82 | 66.6 | 64.19 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.46 | 0.4 | 0.4 | 0.46 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.41 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.75 | 0.81 | 0.8 | 0.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.11 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.21 | 1.21 | 1.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +11% | +14% | +9% | +12% |
| Operating Profit CAGR | -143% | 0% | 0% | 0% |
| PAT CAGR | — | 0% | 0% | 0% |
| Share Price CAGR | -53% | +17% | +28% | +13% |
| ROE Average | -86% | -36% | -30% | +81% |
| ROCE Average | -9% | +1% | +3% | +6% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.44 | 58.58 | 58.58 | 58.58 | 58.58 | 58.58 | 37.83 | 33.14 | 33.14 | 35.61 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.22 | 0.17 |
| DII | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Public | 36.56 | 41.42 | 41.42 | 41.42 | 41.42 | 41.42 | 62.17 | 66.86 | 66.86 | 64.39 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.46 | 0.4 | 0.4 | 0.46 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.41 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.75 | 0.81 | 0.81 | 0.84 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.11 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.21 | 1.21 | 1.3 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.